Drug pay gap socks urology practices, bladder cancer drugs at risk unless CAP is changed

Why This Topic Matters

It highlights a reimbursement problem that can directly affect practice finances and drug acquisition decisions in urology. It also shows how proposed or interim Medicare program changes may affect payment methodology and access for commonly used oncology-related drugs.

Article Sections

1. Drug reimbursement pressures in urology

   This section discusses the overall payment gap affecting urology practices and identifies the broad categories of drugs most impacted. It frames the issue in terms of Medicare payment and practice-level financial strain.

2. Bladder cancer drugs and the competitive acquisition program

   This section addresses concerns about bladder cancer drug purchasing and the Medicare competitive acquisition program. It summarizes the policy issues raised in comments to CMS and the operational concerns for physicians and vendors.

3. Prostate cancer drugs and least costly alternative policies

   This section covers the AUA’s concerns about how least costly alternative policies interact with the newer payment environment. It focuses on broader policy implications for drug administration and program management.

4. Urology drugs originally planned to be in CAP

   This section provides a list of urology-related drugs that were originally planned for inclusion in the competitive acquisition program. It serves as a reference for the scope of the policy discussion.